Company Galena Biopharma Inc Nasdaq

Equities

US3632561086

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

End-of-day quote Nasdaq Other stock markets
- ^USD	-

06-24	SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia	CI
06-17	SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia	CI

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Managers	Title	Age	Since
Angelos Stergiou FOU	Founder	48	02/04/06
John Burns DFI	Director of Finance/CFO	39	30/04/13
Andrew Elnatan LAW	General Counsel	-	04/01/23
Dragan Cicic PRN	Corporate Officer/Principal	60	09/02/20

Members of the board	Title	Age	Since
Robert van Nostrand BRD	Director/Board Member	67	28/12/17
David Scheinberg BRD	Director/Board Member	68	30/11/17
John Varian BRD	Director/Board Member	64	28/12/17
Jane Wasman CHM	Chairman	67	28/12/17
Angelos Stergiou FOU	Founder	48	02/04/06
Katherine Kalin BRD	Director/Board Member	61	12/08/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	57,754,928	57,598,688 ( 99.73 %)	0	99.73 %

Name	Equities	%	Valuation
Anson Funds Management LP 8.367 %	4,832,368	8.367 %	7 M $
Vanguard Global Advisers LLC 2.620 %	1,513,235	2.620 %	2 M $
Geode Capital Management LLC 0.4728 %	273,063	0.4728 %	385 019 $
BlackRock Institutional Trust Co. NA 0.4726 %	272,966	0.4726 %	384 882 $
Opus Capital Group LLC 0.3473 %	200,600	0.3473 %	282 846 $
Equitable Advisors LLC 0.3463 %	200,000	0.3463 %	282 000 $
Dragan Cicic 0.2053 %	118,584	0.2053 %	167 203 $
STATE STREET CORPORATION 0.1682 %	97,129	0.1682 %	136 952 $
Northern Trust Investments, Inc.(Investment Management) 0.1535 %	88,680	0.1535 %	125 039 $
Angelos Stergiou 0.0987 %	56,984	0.0987 %	80 347 $

SELLAS Life Sciences Group, Inc.

Times Square Tower 7 Times Square

10026, New York

http://www.sellaslifesciences.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.56B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs